The chances of the much-touted combination of Seagen Inc./Astellas Pharma, Inc.'s Padcev and Merck & Co., Inc.'s Keytruda getting approval in first-line urothelial cancer would appear to have improved on the back of more positive data presented at the European Society for Medical Oncology conference in Paris.
Cohort K of the Phase Ib/II EV-103/KEYNOTE-869 trial compared a combination of the antibody-drug conjugate Padcev (enfortumab vedotin) and the anti-PD-1 immunotherapy Keytruda (pembrolizumab) in first-line unresectable locally advanced or metastatic urothelial cancer with Padcev monotherapy in cisplatin-ineligible patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?